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AIISTRACT 
Virlually ail l'dis have Lransrcrrin n.:ccptors (a lrallslllcmbwnc glycoprotcin) on their surface, 
but in a normal adult, 80% of them arc in the erythroid marrow. Sorne of them arc lost inlo 
thc circulation whcrc they can be mcasurcd by immuno-assays. A direct and highly signiti~ 
cant correlalion cxisls bclwccn scrum transfcrrin rcccplor Icyel and crylhron transfcrrin upta-
kc in humans. The Illcasurcmcnt of scrum transferrin rcceplar has wide clinical applications 
for the quantitaüon of erythropoiesis. It can be used Lo study erythropoiesis in situations in 
whieh felTokinetics is Ilot acceptable, such aS prcgnancy. It is particularly useful for seriaI SLu-
dies, i.e., for monitoring the recovery of erythropoiesis after stem cclI transplantation or after 
treatmcnl with erythropoictin. Combined with the detcrmination of serum erythropoietin, 
both evaluated in relation to the degree of anemia, they provide a physiological approach to 
the diagnosis of anemÎa. Thus, the simultaneous determination of hematocrit, reticulocytes, 
serum transferrin reccptor and serum erythropoielin has high discriminatory value in distin-
guishing bctween a dcfeet in erythroid proliferation, maturation or red ccII survival. Il is also 
particularly uscful for delecting the presencc or multiple mcehanisms of ancmia in the same 
j1utiel1l. 
INTRODUCTION 
Erythropoiesis is pri1l1arily dependant on erythroid progenitors, their stimulation by erythro-
poietin (Epo), and adequate supply of iroll. 
Epo production by the kidncy is dclerlllined by the Icvel or oxygcn supply which mostly 
depends on the red ccli mass. Epo stimulates red cell production by inducing the proliferation 
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and di!Terentiation of commitled erythroid progenitors. ln Lhe presence of a normal l11arrow 
stcm ceJ1 rcscrve, erythropoiesis will thcrcfore increasc in proportion to the degrce of ancmia. 
ln the last ten years, new tools have been developed for the evaluation of erythropoiesis. This 
paper discusscs the c1inical re1cvance of serum transferrin receplOr and Epo for the quanti ta-
tion or crythropoicsis in man. 
IRON, TRANSFERRIN AND TISSUE TRANSFERRIN RECEPTOR 
The internal Iron cycle consists or iron uptake hy immature erylhroid cells which incorpora-
te !llosl or the iron [ilken up inlo hCllloglohin, the suhsequent circulation of Lhe iron-COJllai-
oing rcd cdl tllrough the v,lscular .<;ystclll. the evelltual proeessing. of senescent or dcfedive 
red cclls hy the rcticulocnuothelial cells (macrophages and KuplTer ecUs) and the reLUrn of 
iron Lo cireulating transferrin. This cycle is driven by eryLhropoicsis. 
Iron Lransport in the plasma is carried out by transrerrin, a single chain glycoprotcin of 80.000 
Dallons. The transferrin gClle is located on chromosome J and there is eviùence thal it Jeri-
ved l'rom a gene duplication event. Transferrin synthesis takes place mostly in the hepatocy-
te and production is increased with iron store depletion and decrcases with repletion. The 
plasma iron poo! is helerogcneous, consisting of apo-, di-, and two fonns of mono-ferrie 
transferrin mo1ccules. Thc lwO monoferric forms have idclltical iron-donating capacity both 
in terms of rate of donation and pauern to tissue distribution. However, there is a 3.5-fold pre-
ference of reccptors for difcrric compared with 1ll0noferrÎc transferrin and removal of iran 
from plasma occurs preferelllially From the pool of diferric molccules. Iron donation to ceIls 
is an ali-or-none phenomenon in which both atoms of iron arc removed sÎlllultaneously from 
dÎferric transferrin. 
The endocytie pathway of transferrin and ilS reeeptor has bcen wcll characterized. At neutral 
pH, the translcrrin rccepLor has very high aUïnity for dilcrric translerrin, intcrmediate affini-
ly for monoferric transferrin, and very littlc for apotransferrin. On the other hand, it forms a 
very stable complex with apotransferrin at pH 5.0. Afler the binding of transferrin to its spe-
cilie surface reccptor, Lhe complex is internalised in an endocytic vesicie or endosome. Duc 
to the acidilication of that organelle, iron is released from the iron-carrying transferrin. In 
contrasl 10 1110st lig<lllds whieh at that point dissociate from their receplOr and enter a path-
way leading [0 fusion with lysosomes and dcgracJation, apotransferrin rcmains bound to its 
reccptor because of the acidic pH. As wiLh many rcccptor systems, the transferrin reccptor is 
rccyclcd to the ccII membrane, carrying apotransJCrrin baek to the ccII surface whcre the ncu-
[rai pH causes its relcase. The duration of lhe intracclJular pathway is betwcen 3 and 16 minu-
tes. 
Virtually ail cclls have transfcn-in receptors on their surface, but the largest numbers are in the 
erythron, placenta, and liver . In a normal adult about 80% of transrerrin receptors are in the 
erythroid marrow, and lhat proportion even augments in situations of stimulated crythro-
poiesis. Rcccptors increase from low Ilumber on erythroid progcnilors 10 a maximum of 
800.000 per ccII on the intermcdiate normoblasts, bcfore dcclining to about 100.000 on reti-
culocytes and none on mature red cells. lt is generally admitled that hcpalocytes express 
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20.000-50.000 rcccptors. Rcccplor dcnsity on cells is rc!alcd to the availabiliLy of iron as 
dcprivation of iron rcsults in prompt induction or transfcrrin rcccptor synthcsis whcrcas 
cxccss iron supprcsscs rcccpLor numbcr (ligure 1). This phcnotllcnon is controlled al the 
transcription Icvcl. 
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* * ** Figure 1: Locatio/l and dell.l'iry of tissue TJR. 
III li normal ac/ul!, abOli! 80% (~/7}R are in the erythroid manvw. With expansion of erylhro-
jJoiesis, the Humber (~f7JR illcreases proporlio!1ally. IlVn deficiency results ill illduction (~fTfR 
synthesis. rfR are represèllfed as triangles (if the sllIface o!rl1t: cells. 
CIRCULATING (SOLUBLE) TRANSFERRIN IŒCEPTOR 
The soluble transrcrrin rcceptor (sTŒ) has been identi!ied in l'al (1) as weil as human serum 
(2). Thc soluble rcceplor is a lruncaled l'orin of lissue reccptor laeking its lirst 100 ami no 
acids, probably dcrived hy cleavagc of the exlracelllliar portion of the reccptor (3). Il circula-
tes in serum in the rorm of a complex of transrcrrin and iLs receplor, possib[y with two rccep-
lor 11l01H)mcrs hinding 10 Olle transfcrrin rnolccule. with a 10«11 molecular wcight of ahout 
250.000 (ligure 2). 
A numbcr or quantitative <Issays, incillding radioiml11unoassays and enzyme -Iinked immu-
noabsorbcnt <lssays using polyclonal or monoclonal antibodics, have now been set up to 
l11easure sTm. in biological nuids. In normal human subjects, receptor levels average 5.000 ± 
J .100 ng/ml. 
The levcl or erylhropoielic activîlY has been round to be the mOSl important determinant of 
sTIR levels (2, 4). Dccreased sTIR Icvcls arc found in situations characlerized by erythroid 
bypoplasia, such as hypertransfusion, chronic renal failure, severe aplastie anemia, or after 
intensive chemotl1erapy. l ncreased sTIR levels arc secn in situations of hcmolysis or stimula-
ted incffective crythropoiesis sueh as immune hemolytic ancmia, hereditary spherocytosis, 
sickle cciI anemia. thalassemia. megaloblaslic ancmia, or sccondary polycythemia. Soluble 
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TIR Icvels range J'rom fi minimum of aboul 700ng/ml (which would reprcsent the eontribu-
lion of non-erythroid lÎssues to serum levels) when crythropoicsis is totaHy suppressed, to 
about [00.000 ng/ml in a severely anemie tha[assemia patient. Incrcascd expression of trans-
ferrin reccptors has becn docull1ented on the surface or malignant [umor cells as compared to 
thcir normal counterparls. However, data on rceeplor Icvc1s in patients with a variety of mye-
/uiJ, lylllphoid and non-hcmutologic malignancjes suggcst tl1at, with the exception of pot y-
cythemia vera, ehronie lymphoeytic lcukaemia and high-grade nOl1-Hodgkin's lymphoma, the 
possible contribution or neoplasic eells LO plasma TiR lcvels is negligiblc. 
The plasma iron lurnover (PIT), in which the dai/y tran.<:,port of iron through the plasma is ca/-
eu/ated l'rom the plasm<t iron and the radioiron disappearanee eurvc aftcr inlravcnous injec-
tion of il Ir;ll'cr dose Ilns hcen cxlcnsivcly uscd as a quantitative 111CaSure or crylhropoicsis (5. 
6). This relutionship is Ineaningfu/ because about 80% of iron passing through the plasma is 
dclivered 10 Ihe erythnlid rnarrow and iroll uplakc or othe!' tissues r'cmains relatively constant. 
Multicompartmenlal modc!s of iron palhways have then bcen proposed Lo quantilate effecti-
ve erythropoiesis, incffcctivc crythropoic~is. l'cd ccillifespan, and non-erythroid iron turnover 
(7, ~). Thcse studies are curnbersomc to perforrn, usually two wecks in duration, and require 
repcated bJood samplings and sophisLicated computer caJeuIations. The use of these models 
is also harnpered by the fael that thcy are based on assumptions which may not aIl be valid, 
and that certain aspects of iron exchangc arc impossible 10 resolve. A simplified approach to 
the rerrokinctic evaluation of erythroid marrow activity has been proposed by Cozzola, and 
TRANSFERRIN RECEPTOR 
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Figure 2: Molecu/urforll/s (~/the TfR. 
The !cft pOllel represenls cellular TfR cOlllposed (~r Iwo 1l/()IWlllers (MW 95;000 cachY linked 
by IwO disuJjide bridges, (/Jld capable of bindillg olle transferrill JIlo/ecule (Closed circle, MW 
80.000), ta give a lotal MW 0/270.000. The right panel represents sTJR, a camplex afTf {lnd 
IWo lIïlI1Ca!ec! mOJ/o1l/ers (MW 85.000 each). ta gil'e a lolo/ MW of250.000. 
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the crythron transfcrrin uptakc (ETU) is now cstabli,shcd as the bCSl avaiJablc mcthod for the 
quantitation of crythropoicsis (9, 10). The dcpcndcncc of sTIR IcvcJs on the aclivily of the 
crylhron i::; further dClllonslratcd by the strong correlation obscrvcd betwccn serum reccptor 
and rcrrokinctic Il1casurCl11cnLs of crythropoicsis. This has hcen shown in rats and confirmcd 
in hUlIlans in who!ll the rclationship hètwccn me an cryLhron transfcrrin uplakc (ETU) and 
mcan sTJR Icve! in subjccLs with a varicty of diagnoses is very close 10 the linc of proportio-
nality (J'rom 0,2 Lo 10 Limes normal) (11). 
Tbe second major uetcrminant of cin..:u!ating TfR is the body Iron stalus. As compared ta nor-
mal values. sTlH. levcls are aholl! 25% lower in patients with idiopathie hcmochromatosis and 
,1hulI! 2011" higlwr ill IHHl-ôllll"lllil' iroll·ddil'il'Il! Sllhjl'l"!S. Thl"s\.' v'lri'lllollS arl" slllalll.:UlllP,I-
red (0 lhosl' dl'll'1"lllinl'd Ily V<lri,l(iolls illl'ry(hnJIH)icsis. 
ERYTHROPOIETIN 
Epo is a glycoprotcin hormone consisting of a single chain of 165 amino acids and four ear-
bohydrale chains eontaining a large amount of sialic aeid, giving a molccular weighl of 
34.000 Daltons. Glycasylation is required for the survival of EPO in circulation, but not 
necessarily for ils biological activity, The gcnc l'or crythropoietin is located on chromosome 
7 and its transcription is aclivaled by hypoxia. 
Epo production Lakes place primarily in peritubular cclls or the kidney that are probably 
cndothc1ial cells or macrophages. Epo is also generated in the liver and in marrow macrop-
hages, but Ihis accounts l'or no more than 10-15% or total production and cannot compensa-
te for 10.'1.'1 or the rcnal source. Epo productioll is regulatcd through a fcedback system bet ween 
Ihe honc marrow and the kidlley which depcnds on a renal oxygcn sensor, possibly a hel11e 
protein : Epo stimulales the honc marrow to producc red ecl1s wh(Jse circulating mass dcler-
mines the renal oxygcn concentration. 
11ll1ll11tHl<lSsays h;lve now replaced bio,lssays sllch <lS the polycythemic mou sc ,lssay or the 
mou se spleen ccii assay for the lllcasurCIll..::nts of serum Epo levcls. Levels in n(Jrmal indivi-
duals arc in the range or 1 () to 25 mU/mI. 
ln the laboralOry ùiagnosis of nnemia, however, serUlll Epo should not be quantitateù in ahso-
lute tenus. ln lact, provided thatthe crythropoiclin-generating apparalUs in the kidney is clli-
denl, lcvcJs inerease cxponcntially as the hcmatoerit deereascs. Consequently, serum Epo 
levcJs must be cxpressed in relation to the hematocrit. This can be done by detennining the 
cxponenlial rcgrcssion of serum Epo versus hcmatoerit in rcference subjects, and ddining the 
95% confidence limits. In c1inical investigations, the adequacy of Epo response ta anemia has 
been generally cvalualCd by comparing the rcgression curve of serum Epo versus hematoerit 
obtained in a group of patients with that of reference subjeels (figure 3). When studying an 
individual patient, appropriateness or Epo response to anemia can be evaluatcd graphically as 
indicatcd in tig.6 or through the observed/predicted log(Epo) ratio (O/P ratio). The O/P ratio 
avcraged 1.00 ± 0.1 1 in our refcrence subjeets (95% con1idence inlerval : 0.80- 1.19) : vaill-
es Jower th en 0,80 indicate an inadequale Epo response to anemia. 
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The wide range of appropriatc Epo levels for ancmic patients suggcst that factors other than 
tissue hypoxia innuence serum Epo (12). In fael, at any givcn hcmatocrit lcvcl, serum Epo is 
higher in patients with Iow crythroid activity compared with patients with hyperplastic eryth-
ropoiesis. Thus the second ma.ior detcrminant or scrum Epo is the red blood ccII precufsor 
Illass (1 J). Il rCllwins Lo be JcLcrlllincd whelhcr the erythroiJ precursor mass acls diret.:lly by 
ulilising circulating Epo or indirectly by inrJuel1eing the rate of Epo production. 
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Figure 3: Regression of Epo 
!eve/s versus Itematocrit in auto-
logoLls (upper regression fine) 
and allogenic (Lower regression 
fille) transplallts. Control subjects 
are representcd by thcir 95% COIl-
.{ldeuee lifni/s (shaded area). 
Reprinted frolll Blood (ref 1 7), 
20 25 30 35 40 45 with permission of the AlIleriean 
HGT (%) Sode/y (4" Neflla!%gy. 
ASSESSMENT OF ERYTHROI'OIESIS BY SERUM TRANSFERRIN RECEPTOR 
AND ERYTHROPOIETIN DETERMINATIONS 
Somc applications arc described along Lhe following lines. 
L Measurcl11ent of crythropoiesis during pregnancy 
pregnaney causes a ri se in plasma volume and l'cd ccli mass wllich reach respectively 150% 
and 120-125% of non-pregnant values near term. Howcver, the talai red cell mass first decre-
ases in early pregnaney, before gradually returnÎng to non-pregnant values by weck 30 and 
further increasing in laIe pregnancy. 
Using the serum TrR assay, il has bccn possible ta show for the lirst time lhal important chan-
ges in the rate of erythropoiesis take place during pregnaney. ln a large sludy, erythropoiesis 
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was shawn to he dcprcssed in carly prcgnancy, la normalizc in the Jïrst part or the third tri-
ITIester, and to incrcasc slightly bcyond normal values in late pregnancy, at dclivcry, and in the 
carly postparlum (14). Allllllsl :')(y!<, or WOIllCll had rcccpLor Jcvcls hclow the lowcr limit or 
normal around wcck 16, but vinually none alkr wcck 37. Although serum Epo \cvcls inerc-
ascd slightly throllghoul prcgnancy, whcn Epo Icvcls were analyscd in relation 10 the hcma-
tocril, both individual1y by O/P ratio and collcclivcly in rcgrcssioll analysis, il was shown thal 
Ero production is impaircd in carly prcgnancy, l'ecoyers in laie prcgnancy, and normalizcs in 
the carly postpartulll (14,15). Whcn prcdiclcd Bpo values were dcrivcd for cach hemalocril 
and an O/P ratio or ohscrvcd/prcdicted log (EPO) was calculated, thcre was a striking paral-
k!islll h~twl'l'n Epo O/P r:1Iio and Tm throughout prcgnancy (ligure 4). Thcrcfore, il11paircd 
crythropoiclin production is rcsponsih!c for dcl"ectivc crythropoicsis in early pregnancy. 
Severa! physiologie illbplilliollS tn pn~gnillley Illily ,wglllent oxygen supply ln the kidney SCI1-
sor, thus ùepressing crythropoietin rclease in the lirst trimesler. 
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Figure 4: Evull/liol/ ofsTfR level.'i 
and Epo OIP ratios througllOlIf 
pregllancy. Epo leve/s relllaill 
insuJJfrient for the degree of alle-
/Ilia in /he jirsl part (l pregllllllcy 
Iml re/um progressivel)' to appro-
priate leve/s Ihereafier. These 
changes in Epo productioll are 
respol1sible for {/ relative er.ythm-
!)()ù!/ic Il/i!lIre lIIlll li correclÎolI 
thereajia 
2. Rccovery of erythropoiesis after stem ecU transplantation 
a) Bonc marrow transplantation 
The clTect or various ractors on the kinetics of neutrophil and platclct engranmcnt al'lcr allo-
genic (BMT) and autologous (ABMT) bane marl"Ow transplantations has bcen extensively 
studicd. Not mueh altention has bcen given erylhrocyte recovery, parti y because of lack of a 
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rc!iablc Illethod to monitor crylhropoic!-iis sequcntially. Again, the sTm. assay provided the 
opportunity to investigate the recovery of erythropoiesis after marrow transplantation (16). 
Contrarily to platelct and nculrophil cngraftmcnl wllieh arc raster arter BMT, erythrocytc 
rccovery is signiJïcantly dclaycd aJkr BMT as cOlllpared to ABMT. Artel" an initial phase 
whcre it SI.X'IllS to rolluw !he saille coursc as in ABMT, crythropoiesis slays at insufficicnt 
intensity for lllonths and l'caches levcls similar to those achicvcd alkr AUTM only al"tcr onc 
year. Epo production in ABMT patients rcmains adcquate throughout the post transplant 
course. Alicr BMT, Epo lcvcls rapidly becamc inappropriatcly low and stays so for prolon-
ged periods or limes (17). Thcrerorc, the developmcnt of erythropoiesis artcr autologous 
transphllltniion is dcLellllillcd hy the ovcndlmmTow proli!"crative capacity ,md Epo plays only 
il J~lci!itating rolc. On the otller haml. artcl" allogenic transplantation, erythropoiesis depends 
Ilil lipl) !cve!.'; which rCIll:lillS inadequate J<)r pl"l)hlllged pL~ri()ds ()J"tillle (ligure 3). 
b) Peripheral blood progcnitor cells (PB PC) transplantation 
The marc reccnt use of PBPC collectcd after ehcmothcrapy and/or growth faetor(s) adminis-
tration has permilled a raster heillatopoietic reconstitution than !.hat seen with the transplan-
tation of bune l11arrow cells. Since Epo production is appropriale in the aUlologous selting, 
this leads ta rapid erylhropoietie engraftmcnt. Indecd, while TtR levels rcaeh their nadir on 
day 7 bath in PBCB and marrow transplants, sTiR retums ta normal values by day 28 in 
PBPC transplants but not within 100 days in marrow transplants (18). 
3. Erythropoiesis in chronic lymphocytic leukaemia and multiple myeloma 
Chronic lymphocyLic leukaemia (CLL) anù multiple myeloma (MM) arc hematologic malig-
nancies whcre anemia devclops with advancing stages (Binet, Durie & Salmon, staging sys-
tems). Ancmia usually progresses in parallcl with marrow infiltration, but several cytokines 
known to inhibil crythropoictin formation arc produced by CLL B cells and myeloma cells. 
In CLL, Epo Icvels arc incrcased comparcd to normal individuals and Lhis clcvation appears 
adequale l'or the ùegrec of ancmia. The slopc or the regrcssion of Epo versus hcmaloerit is 
similar to that uf a reICrencc group. sTIR Icvcls are also appropriately clevated for the degree 
of anemia and correlatc with serum Epo. Advanced stage is not associated with reduetion of 
Epo production bUl ùiminished crythropoiclic activity call he observed in some patients. 
Thercforc, ancmia in CLL is not charactcrized by inadcqu<lte Epo production (19). lncrcased 
hClllolysis and/or splcnic sequestration certainly play a role. 
Anemia is also a frcquent complication of MM. IL lllay occur even in the absence of massive 
marrow replacemenl by ma lignant plasmocytes and in the presence of normal leucocyte and 
platdet eounts. Whcn erythropoiesis is quantitated by serum transfcrrin receptor levels, it 
appears tbat the mcchanism of anemia in MM is primarily dcrectivc red ccII production. 
Erythropoicsis decreascs and anemia worsens sigllificantly with advaneing ç[inieal stage. 
25% of the patients havc inadequale Epo production and this proportion increases to 50% in 
stage 3. lnappropriate Epo production is scen in 60% or patients with renal împairment but is 
also observcù in a numbcr of patients with normal renal function. Erythropoicsis corrclates 
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slrongly with the adequacy or Epo producLÎon, particularly in advanced disease. Thcrcrore, 
rnosl mycloma patients have dcfcctivc l'cd ccII production cven in the absence of massive 
marrow in1ïltration and inappropriatc Epo production conlributes to thcir ancmia (20). 
4. Early prediction of rcsponsc to recombinant human crythropoictin 
ln rcspollsc (0 recombinant IllIlllan cryLllropoictin (l'HuEra), the crylhroblast comparllllcill 
starLs 10 rcspond within a rcw days huI rcquires il period of 6 wecks (() l'ully cxpand hcl'orc 
n.::aching a stcady slalc timing whicll Ihe hClllOglobin continues 10 risc (21). 
a) Anemia or chronic rCll;1I J'ailure 
rHuEpo has bcen shawn 10 he effective in corrccLing the ancmia of chronle renal J'ailure, bUl 
the dose necded may be variable. In thc fm,t years of rHuEpo usage in renal failw·c, a sludy 
was conductcd ta asscss the valuc of varÎous laboratory parametcrs (baseline values and early 
changes) as predictofs of response ta rHuEpo. The best prediction by pre-treatment parame-
ters only was obtained with bascline serum transrerrin reccptor «or;::: 3.500 ng/ml) and 
librinogen « or;::: 4 g/I) : 100% response rate when both parameters were low, versus only 
29% when they were both high, and versus 67% when one was low and the other high. This 
illustrates the importance of /"unctional iron dclïcicncy (higher sTIR) and subclinical inflam-
mation (higher librinogen) in impairing the response ta rHuEpo. Evaluating the early eryth-
ropoielic response to rHuEpo before a signilïcanL change in hematocrit eould be observed was 
also very uscful. ln hemodialysis p;:tlients, a sTIR increment of at least 20% after 2 wceks 
secured a response in virtually 100% of the patients. Thus, the response to rHuEpo could be 
prcdicted early by pre-treatment librinogen an sTtR, together with early changes of sTIR 
levels. Early recognition of a low prohability of response in a given paticnt cou Id help iden-
Lify and correct specifie causes of Lreatmcnl railurc to hasten c1inical improvcmcnt and avoiJ 
prolongcd incffectÎve use of an expcnsivc lllcdication (22). Nowaùays, this implies thc sysle-
mie use of IV iron suppJcmcnwtion to avoicl runcLional iron defleiency. Being so, ncarly ail 
rHuEpo lreatcù patients rcsponù to tbcrapy. 
b) Ancmia of cancer 
Many studics h;:lve shown that rHuEpo therapy can all1cliorale the ancmia associated with 
cancer and chClllothcrapy, reduce the need for transfusions and Îlllprove thc quality 01" lifc. 
Howcver, a Ilumber of di:-;casc- or chemotherapy-rciatcd factors delcrmines the probabilily of 
rcsponsc. Several speciflc mcdwnisms of ancmia, su ch as hel11olysis, splenoll1egaly, blee-
ding, hemodilution or ineffective crylhropoicsis can scriously interl"crc with response. Stem 
ccII damagc by previous therapy will impair responsc and marrow suppression by current 
intensive chemotherapy wil! also have a negative impact. Complications such as infections Of 
nutritional dclïciencies are important response-Iimitîng factors. Because up 10 40% of the 
patients will Ilot respond to rHuEpo, il is of uunost importance ta devclop models that cou Id 
help prcdict rcsponsc to rHuEpo and thus select the most appropriale cancer patients for this 
therapy. The combincd use of baseline serum Epo and the two 2-week sTfR incrcment pro-
vcs to be very powerl"ul, achieving an ovcrall accuracy of 90%. Howcver, carly prediction of 
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responsc baseù on sTIR clevatiQn early in lhe course of treatment will nol be valid in patients 
in whom rHuEpo esscntially stimulalcs ineffective erythropoiesis, for instance patients with 
a myclodysplasic syndrome. 
Erythroid marrow 
hyperplasia 
1 sTfR 1 
[HCt] 
_L Red cel! 
.... mass 
Figure 5: A .'lili/pie fIIodei (~r erylhrojJoiesis. 
t Erythropoietin 
1 sEpo 1 
Anemia (measured by fhe HCf or Hb level) still/u{ates E,'po productio/l by the kidney (lIleas-
/fret! by serum EPO) \vhich il/ [um stilll/l{{/{('s l'IYlhropoiesis (l/Iell.l'ureJ by sT./R). nie retÎcu-
locyte index discrilllÎl1ates belweell ~{feclive and ineffee/ivc crythropoicsis. The physiologie 
asseSSIllCllt (~l J"ed b/oud cel! dison/crs cali be made ill li sillgle Moud sall1ple. 
5. Functional classification of anemia bascd on mcasurcments of serum transferrin 
reccptor, erythropoietin and hematocrit 
Wc evalualcù the quantitativc value or a simple mode! of crythropoiesis, based on the basic 
assumptions Ihat thc reù blood ccII Illass dClcrmines crythropoietin proùuction, which in tum 
stimulatcs erythropoielic activity (lÏgure 5). Instcad or only quantitating Epo and erythro-
poicsis in absolutc terms, wc also evalualcd lhem in relation to the ùcgree of anemia, and 
cxpressed the rcsults as a ratio of obscrvcd values lo values predicted from the rcgression 
cquations between hematocrit one the one band, and Epo and STfR on tbe other. The slopc 
of the rcgrcssion or sTIR versus hematocrit was very similar lo the sJope of the regrcssion of 
Epo versus hematocrÎl (figure 6). We identiJïeù J'our major patterns of erythropoicsis, i.e., nor-
mal, hyperdestruction (wilh variants of hemolysis or incfTective erythropoiesis), intrinsic 
marrow hypoprolifcration, and defective Epo production. The reticulocyles count and index 
was use Cul lo separate hemolysis from ineffectivc erythropoicsis. Thus the pathophysiology 
426 ERYTI-IROPOIETIN - G. FILLET 
of ancmia can be assessed by a simple ll1easuremcnt of hcmatocrit, relie index, Epo and sTIR 
Icvels, with Epo and sTfR bcing more informative when expresscd in relation Lo lhe degrec 
of ancmia. The modcl is partieularly lIseful for delccting the presence 
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Figure 6: Relariollship bellrecl/ 
hematocrit and serum Epo (upper 
panel) or the J'TjR (Iower panel) . 
fn Ihe presence of a normal Epo 
response and a normal nwrmw 
stem cel! reserve, serwil Epo and 
e/:\'Ihropoiesis both il/crease expo-
1Ie1/lial/y in proportion to the deg-
l'ee (~r anemia. Slwded areas are 
the 95% confidence lilllits. Vailles 
45 befoH' this /'al1ge indicale ail il/ap-
propriate reJpol1se 10 anemÎa. 
SOLUBLE TRANSFERRIN RECEPTORAND IRON STATUS 
sTm. is only a markcr of erylhropoicsis whcn iron stores are adcquate and available but addi-
tionally becollles a marker or iron slatus whell tissue iron ùcficicncy occurs. 
a) Iron deficicncy ancmia 
sTIR !cvel is considerably c!cvatcd in îron dericicncy anemia and increases cxponcntially 
with the rcsulting enhanccd erylhropoietic stimulation. 
b) Funclional iron delïcieney 
Functional iron dcJïcicncy îs an imbalance between ifon nceds in the crythropoietic marrow 
and iron supply, which depends on the levcl iron storcs and ils rate of mobilization. An e!c-
1 
" 
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gant sllldy has madc a major contribution to the cvaluation or sTIR as a markcr of lhe iron 
status (24). Whcn normal voluntccrs underwcnl graded phlebotomy, fcrritin dcereascd 
progrcssively whilc sTfR did not change much during the phase of storage iron dcplction. 
Howevcr, sTfR increased signifieantly when marrow functional iron dctïciency and ancmia 
devclopcd. Thcrcfore, the iron stalUs may hc J'ully asscsscd by using serum /"errilin as a mcas-
ure of iron stores (storage iron dcpIClion), sTJR as a measurc of funetional tissue iron dcfi-
cieney (iron deficient erythropoiesis), and hemoglobin as a measurc of advanced iron deJï-
Gieney (iron dcJïcieney ancmia). ,. 
c) ln!lammation 
sTm. rClllains normal in the anclllia or chronic disordcrs. This may help distinguish this cJj-
llic~d prohlclll rrolll iroll dl'licicncy. BJUlllcd Epo production and suppn~ssioJl of erythro-
poiesis by cytokines arc the main reasons for the absence of elevation of sTJR in the anemia 
of inJlal1lJ1lation. 
d) Concomitant iron dc!iciency and Înllalllll1ulion 
Palienls with the anell1ia of chronie disorders ll1ay also have concomitant truc iron deficicn-
ey anù lhen show I>TIR lcvels similarfy clcvatcd as in pure iron dcficicncy ancmia. Contrarily 
to serum {erritin, sTIR may [hus prove 10 be a diagnostic test of iron deficiency in patients 
with inflammation. 
CONCLUSION 
Thc direct rclationship 10 the numbcr of erythroid prccursors and the simple mcthodology 
make sTIR assay thc I11cthod of choicc for evalualion of crylhroid marrow aetivilY in a clini-
cal scUing (iron kinetics in a test tube). The mcasurcmenl or sTIR has wide clinieal applica-
tions for quantitation of erythropoiesis in Immuns and can replace iron kinetics 10 the samc 
extcnt lhal measuremcnt of serum ferritin has rcplaccd bone l11arrow aspiration for quantita-
lion of iron stores. Combined with the measuremcnt of sEpo and reticulocytes eOUI11, ail eva-
lualcd in relation ta thc degree of ancmia, thcy provide a runclional c1assilication of J'cd ccli 
disordcrs : dcfect in proliferation (hypoprolilcrativc ancmia), malUfalÎon (inelTcctivc erythro-
poicsis), or red ccli survival (peripheral hemolysis). They arc a simple and non invasive 
method for the diagnosis or blunted erythropoictin production or inadequate erythroid rnar-
row rcsponsc to anclllia. sTrR il> particuJarly lIseful l'or seriai swdics and for monitoring 
crythrnpoicsis during rHuEpo trcalment. sTfR is only a marker of crylhropoicsis when iron 
stores are present and can be rcadily mobilizcd. fn addition, il is a marker of iron status when 
tissue iroJl dclïcicncy occurs. 
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